AstraZeneca, US6549022043

AstraZeneca stock gains as Enhertu lung-cancer data offsets SERENA-4 setback

Published on 09/14/2026 at 15:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock is up on September 14, 2026, after fresh Phase 3 data showed Enhertu extended progression-free survival in HER2-mutant lung cancer. At the same time, the failed SERENA-4 breast-cancer study highlights the pipeline risk investors must weigh.

Fotorealistisches Pharmaforschungslabor mit Wissenschaftlern in weißen Kitteln an Mikroskopen und Analysegeräten bei hellem klinischen Licht — AstraZeneca US6549022043 zeigt modernes Pharma Forschungslabor mit Wissenschaftlern an Mikroskopen und Analysegeräten, Illustration mit AI erstellt.

AstraZeneca stock (ISIN US6549022043) is trading firmer on September 14, 2026, as investors digest mixed late-stage trial news, with strong Enhertu lung-cancer data helping to counterbalance a recent setback in the SERENA-4 breast-cancer study.

Clinical data drive AstraZeneca stock narrative

According to AstraZeneca on September 14, 2026, the DESTINY-Lung04 Phase III trial showed that ENHERTU monotherapy reduced the risk of disease progression or death by 37.0 percent versus a pembrolizumab-based chemotherapy regimen, with median progression-free survival of 14.3 months compared with 8.3 months for the control arm.

In the same release, the company reported that the hazard ratio for disease progression or death was 0.63 with a 95 percent confidence interval of 0.50 to 0.79 and a p-value of less than 0.0001, underscoring the statistical robustness of the 6.0-month improvement in median progression-free survival for patients with HER2-mutant advanced non-small cell lung cancer.

As Newsquawk reported on September 14, 2026, AstraZeneca also highlighted new data reinforcing Tagrisso as a backbone therapy in EGFR-mutated lung cancer and positive Phase 3 results from DESTINY-Lung04, while acknowledging that its Serena 4 trial in breast cancer did not meet the primary endpoint.

Serena 4 miss and consensus expectations shape risk picture

The risk side of the story comes from AstraZeneca's breast-cancer program. According to Investing.com coverage dated September 14, 2026, AstraZeneca announced late on September 11, 2026, that its Phase 3 SERENA-4 trial of camizestrant in first-line ER-positive, HER2-negative advanced breast cancer failed to demonstrate a statistically significant improvement in progression-free survival versus standard therapy.

In a broader weekly recap, TradingView noted on September 14, 2026, that AstraZeneca reported a mix of clinical outcomes, with positive Phase 3 and Phase 2 data across COPD, HER2-mutant lung cancer, Tagrisso long-term survival and an Imfinzi plus tarlatamab combination, alongside the failed Serena 4 study, while Chief Executive Pascal Soriot warned that potential most-favored-nation pricing policies could put future research and development budgets at risk.

Despite the Serena 4 disappointment, analyst sentiment remains constructive. Based on data compiled by MarketBeat as of September 14, 2026, AstraZeneca stock carries a consensus rating of Moderate Buy from 17 analysts, with 14 rating the shares Buy, two at Hold and one at Sell, and a consensus price target of 206.67 USD.

Analyst targets and recent price action

According to Zonebourse on September 14, 2026, Jefferies reiterated its Buy recommendation on AstraZeneca PLC with a price target of 17,500 GBX, while the stock's last London close was reported at 11,708.0 GBX, implying upside potential of roughly 49.5 percent in the home-currency line if the target is reached.

At the same time, a recent performance overview published on September 14, 2026, noted that AstraZeneca shares on the London Stock Exchange closed at 11,708.0 GBX on September 11, 2026, down 0.43 percent from the prior session, with an intraday high of 11,960.0 GBX and volume of about 1.47 million shares.

The same overview reported that over the five trading days up to September 11, 2026, AstraZeneca stock fell 2.48 percent and was down 15.10 percent since the start of 2026, underperforming the FTSE 100 index and illustrating how the recent clinical and macro headlines are playing out against a weaker share-price trend year to date.

For U.S. investors following the American depositary shares, the New York line provides an additional lens. According to the same price snapshot, AstraZeneca's U.S.-listed shares ended September 11, 2026, at 160.17 USD, posting a 0.33 percent gain on that day and diverging from the modest decline in the London listing.

Stock level and investor takeaway

On the home market, AstraZeneca stock was quoted at 12,086.0 GBX in London trading with a 3.25 percent gain and volume of around 1.05 million shares as of September 14, 2026, according to a latest overview from Investing.com UK, suggesting that the positive lung-cancer data is being reflected in the share price after the Serena 4 setback.